Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| CYTK | CYTOKINETICS INC | 2026-03-03 13:35:19 | 60.92 | -0.51 | -0.83 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CYTK | 0001061983 | CYTOKINETICS INC | US23282W6057 | 549300BE5DY1HW7IHA64 | 943291317 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | — | 350 OYSTER POINT BOULEVARD | SOUTH SAN FRANCISCO | CA | 94080 | UNITED STATES | US | (650) 624-3000 | 350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080 | 350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080 | — | — | 1997 | Robert Blum | 423 | https://cytokinetics.com | 5,600,000,000 | 118,209,139 | 122,264,929 | Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. | 2026-02-26 16:15:03 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 2,500,000,000 | -3,100,000,000 | -55.3571 | 123,162,807 | 4,752,118 | 4.0133 |
| 2024 | 5,600,000,000 | 3,600,000,000 | 180 | 118,410,689 | 15,405,979 | 14.9566 |
| 2023 | 2,000,000,000 | 0 | 0 | 103,004,710 | 7,843,319 | 8.2421 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Sung H. Lee | Principal Financial Officer | 2024 | 550,000 | 80,000 | 3,352,526 | 177,522 | 86,410 | 5,918,931 |
| Fady I. Malik | Executive Vice President | 2024 | 609,464 | 0 | 3,399,979 | 287,972 | 12,333 | 5,371,389 |
| Robert I. Blum | Principal Executive Officer | 2024 | 825,550 | 0 | 9,800,033 | 681,079 | 1,688 | 14,368,343 |
| Andrew M. Callos | Chief Commercial Officer, Executive Vice President | 2024 | 562,913 | 0 | 2,700,004 | 269,143 | 13,909 | 4,389,027 |
| Brett Pletcher | Chief Legal Officer, Executive Vice President | 2024 | 560,000 | 100,000 | 2,694,347 | 99,031 | 0 | 5,420,492 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 673 |
| 2024 | 498 |
| 2023 | 423 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 88,039,000 | 18,474,000 | 7,530,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 416,026,000 | 339,408,000 | 330,123,000 |
| General And Administrative Expenses | 284,271,000 | 215,314,000 | 173,612,000 |
| Operating Expenses | 700,297,000 | 554,722,000 | 503,735,000 |
| Operating Income | -612,258,000 | -536,248,000 | -496,205,000 |
| Net Income | -784,955,000 | -589,526,000 | -526,244,000 |
| Earnings Per Share Basic | -6.54 | -5.26 | -5.45 |
| Earnings Per Share Diluted | -6.54 | -5.26 | -5.45 |
| Weighted Average Shares Outstanding Basic | 120,103 | 111,979 | 96,524 |
| Weighted Average Shares Outstanding Diluted | 120,103 | 111,979 | 96,524 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 122,518,000 | 94,857,000 | 113,024,000 |
| Marketable Securities Current | 759,703,000 | 981,157,000 | 501,800,000 |
| Accounts Receivable | 17,764,000 | 16,650,000 | 1,283,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 916,975,000 | 1,107,940,000 | 628,051,000 |
| Marketable Securities Non Current | 335,048,000 | 145,055,000 | 40,534,000 |
| Property Plant And Equipment | 79,194,000 | 65,815,000 | 68,748,000 |
| Other Assets Non Current | 17,341,000 | 7,705,000 | 7,996,000 |
| Total Assets Non Current | 507,562,000 | 293,733,000 | 196,265,000 |
| Total Assets | 1,424,537,000 | 1,401,673,000 | 824,316,000 |
| Accounts Payable | 22,337,000 | 20,369,000 | 21,507,000 |
| Deferred Revenue | 1,612,000 | 52,370,000 | — |
| Short Term Debt | 41,181,000 | 11,520,000 | 10,080,000 |
| Other Liabilities Current | 3,833,000 | 9,814,000 | 10,559,000 |
| Total Liabilities Current | 202,452,000 | 179,674,000 | 102,678,000 |
| Long Term Debt | 246,384,000 | 619,521,000 | 639,268,000 |
| Other Liabilities Non Current | — | 0 | 186,000 |
| Total Liabilities Non Current | 1,881,710,000 | 1,357,371,000 | 1,107,961,000 |
| Total Liabilities | 2,084,162,000 | 1,537,045,000 | 1,210,639,000 |
| Common Stock | 123,000 | 118,000 | 102,000 |
| Retained Earnings | -3,486,719,000 | -2,701,764,000 | -2,112,238,000 |
| Accumulated Other Comprehensive Income | 630,000 | 2,398,000 | -10,000 |
| Total Shareholders Equity | -659,625,000 | -135,372,000 | -386,323,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 10,125,000 | 9,531,000 | 11,892,000 |
| Share Based Compensation Expense | 112,286,000 | 97,840,000 | 72,065,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 1,114,000 | 15,367,000 | 1,136,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 2,663,000 | -4,483,000 | -3,483,000 |
| Change In Other Liabilities | 33,603,000 | 14,182,000 | 17,103,000 |
| Cash From Operating Activities | -510,009,000 | -395,890,000 | -414,333,000 |
| Purchases Of Marketable Securities | 1,063,173,000 | 1,293,416,000 | 635,211,000 |
| Sales Of Marketable Securities | 6,001,000 | 0 | 4,975,000 |
| Acquisition Of Property Plant And Equipment | 24,807,000 | 3,906,000 | 1,416,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 16,666,000 | -553,097,000 | 239,253,000 |
| Tax Withholding For Share Based Compensation | 2,468,000 | 19,631,000 | 10,517,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 0 | 93,640,000 | 164,233,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 10,809,000 | 8,679,000 | — |
| Other Financing Activities | 35,979,000 | 53,016,000 | 18,459,000 |
| Cash From Financing Activities | 524,458,000 | 930,611,000 | 221,317,000 |
| Change In Cash | 30,400,000 | -18,167,000 | 46,217,000 |
| Cash At End Of Period | 122,518,000 | 94,857,000 | 113,024,000 |
| Income Taxes Paid | 0 | — | — |
| Interest Paid | 22,914,000 | 25,970,000 | 10,295,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -6.54 | -5.26 | -5.45 |
| Price To Earnings Ratio | -9.7156 | -8.943 | -15.3193 |
| Earnings Growth Rate | 24.3346 | -3.4862 | 25.8661 |
| Price Earnings To Growth Ratio | -0.3993 | 2.5652 | -0.5923 |
| Book Value Per Share | -5,492.1609 | -1,208.9052 | -4,002.3517 |
| Price To Book Ratio | -0.0116 | -0.0389 | -0.0209 |
| Ebitda | -729,251,000 | -542,294,000 | -486,046,000 |
| Enterprise Value | 172,678,344.62 | 541,451,492.16 | 544,382,788.76 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -0.436 | -4.6615 | -1.6808 |
| Capital Expenditures | 23,504,000 | 6,598,000 | 187,000 |
| Free Cash Flow | -533,513,000 | -402,488,000 | -414,520,000 |
| Return On Equity | 1.19 | 4.3549 | 1.3622 |
| One Year Beta | 0.6017 | 1.2359 | 1.3166 |
| Three Year Beta | 0.9121 | 1.0977 | 1.1105 |
| Five Year Beta | 0.9876 | 0.9926 | 0.9849 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Callos Andrew | EVP, Chief Commercial Officer | 2026-03-02 | 886 | A | 51,326 |
| Callos Andrew | EVP, Chief Commercial Officer | 2026-03-02 | 886 | D | 50,440 |
| Callos Andrew | EVP, Chief Commercial Officer | 2026-03-02 | 886 | D | 0 |
| PARSHALL B LYNNE | Director | 2026-03-02 | 5,000 | D | 17,933 |
| Callos Andrew | EVP, Chief Commercial Officer | 2026-02-05 | 15,000 | A | 65,440 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | 2025-11-18 | CA31 | Purchase | 2025-10-09 | — | $1,001 - $15,000 |
| Lisa McClain | 2025-08-13 | MI09 | Sale | 2025-06-17 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-08-13 | MI09 | Purchase | 2025-06-11 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Caitong International Asset Management Co., Ltd | 2025-12-31 | 381 | 6 | 63.5 |
| Alpine Global Management, LLC | 2025-12-31 | 381,240 | 6,000 | 63.54 |
| Bell Investment Advisors, Inc | 2025-12-31 | 2,288 | 36 | 63.5556 |
| Pacer Advisors, Inc. | 2025-12-31 | 1,765,332 | 27,783 | 63.54 |
| MV CAPITAL MANAGEMENT, INC. | 2025-12-31 | 4,385 | 69 | 63.5507 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| MASSMUTUAL SELECT FUNDS | 2025-12-31 | Class R3 | MSGNX | 33,804 | 2,147,906.16 | 0.378 |
| MASSMUTUAL SELECT FUNDS | 2025-12-31 | Administrative Class | MSGLX | 33,804 | 2,147,906.16 | 0.378 |
| MASSMUTUAL SELECT FUNDS | 2025-12-31 | Class A | MMGEX | 33,804 | 2,147,906.16 | 0.378 |
| T. Rowe Price Exchange-Traded Funds, Inc. | 2025-12-31 | T. Rowe Price Health Care ETF | TMED | 6,343 | 403,034.22 | 2.4691 |
| T. Rowe Price Exchange-Traded Funds, Inc. | 2025-12-31 | T. Rowe Price Capital Appreciation Premium Income ETF | TCAL | 30,360 | 1,929,074.4 | 0.9169 |